Rosetta Genomics Granted US Patent for miRNA Used in Diagnostic Tests

The patent protects human hsa-miR-497, an "important component" of Rosetta's miRview Mets and miRview Mets2 diagnostic tests, used to identify the tissue of origin in cancers of unknown primary.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.